Qlucore AB (publ) Total Liabilities
Qlucore AB (publ) total liabilities. Based on the latest financial reports, Qlucore AB (publ) (NOVKAN) has total liabilities worth Skr1.67 Million SEK (≈ $179.61K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See NOVKAN days of operational coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Qlucore AB (publ) (2010–2025)
Total liabilities of Qlucore AB (publ) from 2010 to 2025. This chart illustrates how Qlucore AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Check Qlucore AB (publ) asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Qlucore AB (publ) Competitors by Total Liabilities
The table below lists competitors of Qlucore AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Duearity AB
ST:DEAR
|
Sweden | Skr22.38 Million |
|
Challenger Energy Group PLC
LSE:CEG
|
UK | GBX13.66 Million |
|
DETALION GAMES SA ZY -10
F:9XJ
|
Germany | €592.89K |
|
LogicMark Inc
NASDAQ:LGMK
|
USA | $2.03 Million |
|
Cordel Group PLC
LSE:CRDL
|
UK | GBX1.16 Million |
|
Arcadia Biosciences Inc
NASDAQ:RKDA
|
USA | $2.41 Million |
|
Dewhurst plc
LSE:DWHA
|
UK | GBX10.81 Million |
|
Sanco Industries Limited
NSE:SANCO
|
India | Rs687.89 Million |
Liability Composition Analysis (2010–2025)
This chart breaks down Qlucore AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NOVKAN asset base.
Liquidity & Leverage Metrics
Qlucore AB (publ) Total Liabilities Ratios Explained
Qlucore AB (publ) total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Qlucore AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Qlucore AB (publ) (2010–2025)
The table below shows the annual total liabilities of Qlucore AB (publ) from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr1.67 Million ≈ $179.61K |
-63.80% |
| 2024-12-31 | Skr4.61 Million ≈ $496.22K |
-74.35% |
| 2023-12-31 | Skr17.98 Million ≈ $1.93 Million |
+30.03% |
| 2022-12-31 | Skr13.83 Million ≈ $1.49 Million |
+27.19% |
| 2021-12-31 | Skr10.87 Million ≈ $1.17 Million |
+0.47% |
| 2020-12-31 | Skr10.82 Million ≈ $1.16 Million |
-59.83% |
| 2019-12-31 | Skr26.93 Million ≈ $2.90 Million |
+121.21% |
| 2018-12-31 | Skr12.18 Million ≈ $1.31 Million |
-2.70% |
| 2017-12-31 | Skr12.51 Million ≈ $1.35 Million |
-7.35% |
| 2016-12-31 | Skr13.51 Million ≈ $1.45 Million |
+146.21% |
| 2015-12-31 | Skr5.49 Million ≈ $590.38K |
-39.92% |
| 2014-12-31 | Skr9.13 Million ≈ $982.64K |
+36.43% |
| 2013-12-31 | Skr6.69 Million ≈ $720.27K |
-49.18% |
| 2012-12-31 | Skr13.17 Million ≈ $1.42 Million |
-4.82% |
| 2011-12-31 | Skr13.84 Million ≈ $1.49 Million |
+370.04% |
| 2010-12-31 | Skr2.94 Million ≈ $316.82K |
-- |
About Qlucore AB (publ)
Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study… Read more